Abstract
Benign prostate hyperplasia (BPH) is a major disease and its non-surgical therapy a major area of interest. The purpose of this study was to establish perfusion parameters in beagles with BPH using dynamic contrast-enhanced (DCE) MRI and to investigate changes due to the effects of finasteride treatment. Twelve male beagles (mean age 4.4±0.9,years) were divided into a control and treatment group that received a daily dose of 1 mg/kg finasteride. DCE MRI was carried out in a clinical scanner using a 3D spoiled gradient echo sequence prior to and during treatment. 0.2 mmol/kg contrast agent (gadoteridol) was administered with an injection rate of 0.2 ml/s followed by a 15 ml flush of saline. Contrast enhancement was evaluated by pharmacokinetic mapping of a two-compartment model with colour overlay images in addition to regional ROI analysis. Quantitative parameters were defined by the amplitude of contrast enhancement A, the exchange rate kep and the time to maximum signal enhancement. Dynamic contrast-enhanced MRI investigations of the prostate revealed two distinct zones, an inner, periurethral zone and an outer, parenchymal zone. The periurethral zone is highly vascularized, whereas the parenchymal zone is moderately vascularized when compared to other parenchymal organs. During treatment, in the parenchymal zone the intensity of enhancement (amplitude A) and the time to maximum signal enhancement increased, while the exchange rate kep decreased. Dynamic contrast-enhanced MRI of BPH reveals distinct differences between individual zones within the prostate. Moreover, changes during successful treatment suggest increased blood volume per volume of tissue and decreased vessel leakiness.
Similar content being viewed by others
References
Juniewicz PE, Berry SJ, Coffey DS, Strandberg JD, Ewing LL (1994) The requirement of the testis in establishing the sensitivity of the canine prostate to develop benign prostatic hyperplasia. J Urol 152:996–1001
Berry SJ, Coffey DS, Ewing LL (1986) Effects of aging on prostate growth in beagles. Am J Physiol 250:R1039–R1046
Brendler CB, Berry SJ, Ewing LL, McCullough AR, Cochran RC, Strandberg JD, Zirkin BR, Coffey DS, Wheaton LG, Hiler ML, Bordy MJ, Niswender GD, Scott WW, Walsh PC (1983) Spontaneous benign prostatic hyperplasia in the beagle: age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. J Clin Invest 71:1114–1123
Gloyna RE, Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. II . The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog. J Clin Invest 49:1746–1753
Chang WY, Shidaifat F, Chang CJ, Kulp SK, Sugimoto Y, Canatan H, Brueggemeier RW, Lin YC (1996) Experimentally-induced prostatic hyperplasia in young beagles: a model to evaluate the chemotherapeutic effects of gossypol. Res Commun Mol Pathol Pharmacol 92:341–360
Murakoshi M, Ikeda R, Fukui N (2001) The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia. J Toxicol Sci 26:119–127
Berry SJ, Strandberg JD, Saunders WJ, Coffey DS (1986) Development of canine benign prostatic hyperplasia with age. Prostate 9:363–373
Moore RJ, Gazak JM, Quebbeman JF, Wilson JD (1979) Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog. J Clin Invest 64:1003–1010
Gambert SR, Gupta K (1995) Endocrine aspects of aging. Endocrinology and metabolism clinics of North America 8:213–457
Murakoshi M, Inada R, Makino M, Suzuki M, Mieda M, Honma S, Yamanaka H (1990) Effect of anti-androgen (TZP-4238) on steroid-induced canine prostatic hyperplasia. Light and electron microscopic investigations. Acta Pathol Jpn 40:871–879
de la Rosette JJ, Gravas S, Muschter R, Rassweiler J, Joyce A (2003) Present practice and development of minimally invasive techniques, imaging and training in European urology: results of a survey of the European society of uro-technology (ESUT). Eur Urol 44:346–351
Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ (2003) A prospective evaluation of detrusor ultrastructural changes in bladder outlet obstruction. BJU Int 91:360–364
Hoffmann AL, Laguna MP, de la Rosette JJ, Wijkstra H (2003) Quantification of prostate shrinkage after microwave thermotherapy: a comparison of calculated cell-kill versus 3D transrectal ultrasound planimetry. Eur Urol 43:181–187
Tubaro A, Trucchi A, Miano L (2003) Investigation of benign prostatic hyperplasia. Curr Opin Urol 13:17–22
Cohen SM, Taber KH, Malatesta PF, Shpungin J, Berman C, Carlin JR, Werrmann JG, Prahalada S, Bryan RN, Cordes EH (1991) Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia. Magn Reson Med 21:55–70
Choyke PL, Dwyer AJ, Knopp MV (2003) Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17:509–520
Knopp MV, Giesel FL, Marcos H, Tengg-Kobligk H, Choyke P (2001) Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 12:301–308
Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621–628
Berry SJ, Coffey DS, Strandberg JD, Ewing LL (1986) Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia. Prostate 9:295–302
Brooks JR, Berman C, Garnes D, Giltinan D, Gordon LR, Malatesta PF, Primka RL, Reynolds GF, Rasmusson GH (1986) Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors. Prostate 9:65–75
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heverhagen, J., Tengg-Kobligk, H., Baudendistel, K. et al. Benign prostate hyperplasia: evaluation of treatment response with DCE MRI. MAGMA 17, 5–11 (2004). https://doi.org/10.1007/s10334-004-0040-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10334-004-0040-1